One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
PetIQ logo
PetIQ PETQ
report update icon

Quarterly report 2024-Q2
added 07-04-2026

PetIQ Balance Sheet 2023-2011 | PETQ

Brief balance sheet overview of PetIQ

The review uses the five latest available annual reports between 2016 and 2020.

The asset base grew from $81.3 million to $771.6 million, or +848.7%. Average annual growth of roughly 75.5% was strong.

Asset growth of +848.7% came with a +1,083.6% rise in liabilities. Financial leverage became more prominent.

Equity finances 31.9% of the balance sheet, compared with 50.4% at the start. The cushion remains adequate.

Net debt to equity stands at 1.34x; debt servicing is an important part of overall resilience.

Cash equals 4.3% of the balance sheet, compared with 0.9% five periods ago. This is the readily available cushion.

The balance sheet includes a negative accumulated result of -$93.4 million. It should be assessed alongside historical profits and capital distributions.

Overall picture

PetIQ's balance sheet presents a mixed picture: strengths coexist with a limited cushion. Future capital and debt trends are particularly important.

Annual Balance Sheet PetIQ

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

329 M 349 M 376 M 375 M 229 M 41.9 M -20.7 M 27.1 M 29.4 M - - - -

Long Term Debt

438 M 443 M 448 M 404 M 251 M 107 M 17.2 M 25.2 M 32.1 M - - - -

Long Term Debt Current

7.61 M 6.6 M 6.5 M 4.92 M 4.62 M 796 K 44 K - - - - - -

Total Non Current Liabilities

456 M 458 M 466 M 424 M 271 M 110 M 17.8 M 27.3 M 34.9 M - - - -

Total Current Liabilities

190 M 149 M 98.1 M 101 M 73 M 64.2 M 18.2 M - - - - - -

Total Liabilities

- - - 478 M 344 M 174 M 36 M 40.3 M 46.1 M - - - -

Retained Earnings

-161 M -163 M -115 M -98.6 M -15.9 M -4.45 M -3.49 M - - - - - -

Total Assets

868 M 819 M 820 M 772 M 673 M 495 M 141 M 81.3 M 92.3 M - - - -

Cash and Cash Equivalents

116 M 101 M 79.4 M 33.5 M 27.3 M 66.4 M 37.9 M 767 K 3.25 M - - - -

Book Value

868 M 819 M 820 M 294 M 328 M 321 M 105 M 41 M 46.3 M - - - -

Total Shareholders Equity

223 M 212 M 255 M 246 M 328 M 321 M 105 M 41 M 46.3 M - - - -

All numbers in USD currency

Quarterly Balance Sheet PetIQ

2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

436 M 436 M 439 M 441 M 442 M - 445 M 451 M 473 M 448 M 438 M 455 M 443 M 404 M 355 M 358 M 325 M 251 M 255 M 99.7 M 115 M 107 M 108 M 107 M 127 M 17.2 M 19.9 M 17.2 M 17.2 M 25.2 M 25.2 M - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

451 M 453 M 453 M 456 M 458 M - 460 M 468 M 490 M 466 M 458 M 474 M 463 M 424 M 375 M 379 M 345 M 271 M 274 M 111 M 125 M 110 M 117 M 117 M 139 M 17.8 M 20.7 M 17.8 M 17.8 M 27.3 M 27.3 M - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-130 M -146 M -143 M -144 M -153 M - -156 M -107 M -111 M -115 M -100 M -92.5 M -96.5 M -98.6 M -83 M -19.9 M -18 M -15.9 M -4.91 M 976 K -2.84 M -4.45 M -976 K -3.2 M -5.7 M -3.49 M -226 K -3.49 M -3.49 M - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

894 M 875 M 857 M 883 M 868 M - 792 M 855 M 924 M 820 M 827 M 843 M 853 M 772 M 778 M 867 M 777 M 673 M 690 M 524 M 535 M 495 M 409 M 400 M 402 M 141 M 145 M 141 M 141 M 81.3 M 81.3 M - - 92.3 M - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

84.1 M 25.4 M 125 M 78.4 M 25.4 M - 56.7 M 5.4 M 51.1 M 79.4 M 63.2 M 27.2 M 11.1 M 33.5 M 57.8 M 117 M 28.1 M 27.3 M 10.5 M 36.6 M 54.4 M 66.4 M 4.48 M 11.7 M 4.71 M 37.9 M 46.5 M 37.9 M 37.9 M 767 K 767 K - - 3.25 M - - - 1.37 M - - - - - - - - - - - - - - -

Book Value

894 M 875 M 857 M 883 M 868 M - 792 M 855 M 924 M 820 M 827 M 843 M 853 M 772 M 778 M 867 M 777 M 673 M 690 M 524 M 535 M 495 M 409 M 400 M 402 M 141 M 145 M 141 M 141 M 81.3 M 81.3 M - - 92.3 M - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

260 M 238 M 239 M 236 M 223 M - 215 M 267 M 261 M 255 M 263 M 270 M 257 M 246 M 302 M 363 M 332 M 328 M 336 M 338 M 329 M 321 M 239 M 209 M 200 M 105 M 108 M 105 M 105 M 41 M 41 M - - 46.3 M - - - 48.1 M - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of PetIQ, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Drug manufacturers

Issuer Price % 24h Market Cap Country
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
Pacira BioSciences Pacira BioSciences
PCRX
$ 36.48 0.04 % $ 1.63 B usaUSA
Perrigo Company plc Perrigo Company plc
PRGO
$ 16.83 -0.71 % $ 2.33 B usaUSA
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 7.19 2.35 % $ 629 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.4 -0.36 % $ 361 M canadaCanada
Tilray Tilray
TLRY
$ 2.66 -6.84 % $ 297 M canadaCanada
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Veru Veru
VERU
$ 2.12 -3.2 % $ 31.1 M usaUSA
Viatris Viatris
VTRS
$ 20.86 1.81 % $ 23.9 B usaUSA
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
cbdMD cbdMD
YCBD
$ 0.39 1.86 % $ 1.57 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
China Pharma Holdings China Pharma Holdings
CPHI
$ 0.55 -2.64 % $ 2.36 M chinaChina
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 0.59 -5.37 % $ 176 M canadaCanada
Aurora Cannabis Aurora Cannabis
ACB
$ 5.11 -1.07 % $ 280 M canadaCanada
Harrow Health Harrow Health
HROW
$ 30.4 10.67 % $ 1.12 B usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 5.39 0.37 % $ 80.1 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 4.24 2.42 % $ 167 M usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 6.04 -0.98 % $ 323 M usaUSA
Cronos Group Cronos Group
CRON
$ 3.43 -3.25 % $ 1.32 B canadaCanada
Evolus Evolus
EOLS
$ 6.81 -2.51 % $ 439 M usaUSA
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 0.96 5.83 % $ 122 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 8.33 -0.83 % $ 3.09 B canadaCanada
OrganiGram Holdings OrganiGram Holdings
OGI
$ 0.85 -2.69 % $ 81 M canadaCanada
Rockwell Medical Rockwell Medical
RMTI
$ 7.35 -2.26 % $ 264 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 3.54 1.14 % $ 177 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.12 -0.88 % $ 1.89 M usaUSA
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.74 2.96 % $ 20.1 M usaUSA
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
- - $ 150 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA